hrp0086p1-p117 | Bone & Mineral Metabolism P1 | ESPE2016

No Severe Hypercalcemia During a 12-Month High-Dose Vitamin D Intervention in Infants

Enlund-Cerullo Maria , Valkama Saara , Holmlund-Suila Elisa , Rosendahl Jenni , Hauta-alus Helena , Viljakainen Heli , Andersson Sture , Makitie Outi

Background: Vitamin D supplementation is widely recommended to infants, but the optimal dose remains unclear. Vitamin D regulates calcium metabolism, and overdosing and high intake may result in hypercalcemia.Objective and hypotheses: We measured serum pH-adjusted ionized calcium (Ca-ion/pH 7.40) concentrations at 6 and 12 months and 25-hydroxyvitamin D (S-25-OHD) at 12 months in order to evaluate the risk of hypercalcemia during vitamin D3 su...

hrp0086p1-p204 | Diabetes P1 | ESPE2016

A Syndrome of Permanent Neonatal Diabetes Mellitus and Neurological Abnormalities due to a Novel Homozygous Missense c.449T>A (p.I150N) Mutation in NEUROD1 Gene

Hatipoglu Nihal , Demirbilek Huseyin , Gul Ulku , Tatli Zeynep Uzan , Flanagan Sarah , Ellard Sian , De Franco Elisa , Kurtoglu Selim

Neonatal diabetes mellitus (NDM) is a rare form of monogenic diabetes presenting in the first 6 months of life. NEUROD1 is a transcriptional factor involved in the development of endocrine pancreas. A few patients with maturity onset diabetes of the young (MODY) due to heterozygous NEUROD1 mutations and only two cases with permanent NDM (PNDM) associated to neurological disorders and cerebellar hypoplasia due to homozygous mutations in the NEUROD1 gene have been reported.<...

hrp0086p1-p212 | Diabetes P1 | ESPE2016

Permanent Neonatal Diabetes Mellitus due to a Novel Homozygous GCK Mutation in a Premature Baby with IUGR and Its Management

Braha Nirit , De Franco Elisa , Dawes Adam , Sharples Kate , Moodambail Abdul , Hughes Claire , Ellard Sian , Gevers Evelien

Background: Glucokinase (GCK) acts as the glucose sensor of β-islet cells, regulating insulin secretion in response to changing glucose concentrations. Homozygous GCK mutations are a rare cause of permanent neonatal diabetes. Heterozygous mutations lead to GCK MODY, causing mild hyperglycaemia, not usually requiring treatment.Case: The index case was born to consanguineous parents at 36+2 weeks gestation, weighing 1610 g (0.4th centile). Hy...

hrp0086p1-p218 | Diabetes P1 | ESPE2016

Clinical Characteristics and Molecular Analysis of Patients with Neonatal Diabetes

Yavas Abali Zehra , Bundak Ruveyde , Bas Firdevs , De Franco Elisa , Genens Mikayir , Poyrazoglu Sukran , Ellard Sian , Hattersley Andrew , Darendeliler Feyza

Background: Neonatal diabetes mellitus (NDM) is a form monogenic diabetes diagnosed under 6 month of age.Objective and hypotheses: To describe the clinical and molecular features of NDM patients in a Turkish cohort.Method: Fifteen patients (13M, 2F) with diabetes onset before 6 months of age were included in the study. Clinical and molecular data were evaluated retrospectively.Results: Mean age at diagnosis w...

hrp0086p2-p305 | Diabetes P2 | ESPE2016

Thiamine Responsive Megaloblastic Anemia Due to SLCA19A2 Gene Mutation: Another Cause of Neonatal Diabetes with Succcesfull Switch from Insulin to Thiamine

Bas Serpil , Akbarzade Azad , Atay Zeynep , Gurbanov Ziya , Guran Tulay , Turan Serap , Franco Elisa De , Ellard Sian , Bereket Abdullah

Itroduction: Thiamine responsive anemia (TRMA) known as Rogers syndrome; is an early-onset, autosomal recessive disorder characterized by diabetes mellitus, megaloblastic anemia and sensorineural deafness. Diabetes in this condition is well described in infancy but has only very rarely been reported in association with neonatal diabetes.Case: 3-months old male patient with neonatal diabetes was admitted to our outpatient clinic because of uncontrolled hy...

hrp0086p2-p584 | Perinatal Endocrinology P2 | ESPE2016

A Unique IL2RA Mutation Presenting as Neonatal Diabetes, Congenital Hypothyroidism and Sepsis

Sri Nagesh V. , Hattersley Andrew , Ellard Sian , De Franco Elisa , Flanagan Sarah , Naseem Altaf , Ahmed A. , Ahmed Tanveer , Venkateswarlu K.

Background: 16 year old female neonate presented with neonatal diabetes, congenital hypothyroidism and sepsis.Objective and hypotheses: To evaluate the neonate for a common cause of neonatal diabetes, congenital hypothyroidism and sepsis and to explore for the best modality of management, including a possible role for sulphonylureas.Method: The neonate born of 3rd degree consanguinity was admitted and started on insulin infusion an...

hrp0082fc3.6 | Diabetes | ESPE2014

Alpha-Lipoic Acid and Anti-Oxidant Diet Helps to Improve Endothelial Dysfunction in Children and Adolescents with Type 1 Diabetes

Scaramuzza Andrea , Ungheri Saverio , Redaelli Francesca , Bosetti Alessandra , Giani Elisa , Ferrari Matteo , Comaschi Valentina , Giudici Valentina , Zuccotti Gian Vincenzo

Background: Endothelial dysfunction is a macrovascular complication of type 1 diabetes. Children and adolescents with type 1 diabetes may suffer of endothelial dysfunction, irrespective of chronological age and disease duration.Objective and hypotheses: After evaluating the prevalence of early endothelial dysfunction, as measured by mean of reactive hyperaemia in adolescents with type 1 diabetes, at baseline and after 1-year follow-up, we started a 6-mon...

hrp0084p2-422 | GH &amp; IGF | ESPE2015

Physical Performance and Right Ventricular Function in Children with GH Deficiency before and after 12 Months-GH Replacement Therapy

Barbieri Flavia , Capalbo Donatella , Lucci Rosa , Vitelli Alessandra , Esposito Andrea , Di Pietro Elisa , Rapacciuolo Antonio , Vigorito Carlo , Salerno Mariacarolina

Background: Several metabolic abnormalities, including unfavourable lipid profile, impaired cardiac performance, muscle strength and endurance capacity have been documented in GH Deficiency (GHD) adults. Alterations in cardiac morphology and left ventricular function and early markers of cardiovascular risk have been also detected in GHD children; however, no studies have so far investigated the effects of GHD on physical performance and right ventricular (RV) function in chil...

hrp0097rfc2.5 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Growth in young children with X-linked hypophosphatemia treated with burosumab

Ertl Diana-Alexandra , Sala Elisa , Trabado Séverine , Audrain Christelle , Berkenou Jugurtha , Rothenbuhler Anya , Lambert Anne-Sophie , Linglart Agnes

Background: Disproportionate short stature is seen in most individuals with X-linked hypophosphatemia (XLH). Vitamin D and phosphate supplementation can improve growth slightly. Burosumab showed minimal improvement of growth in older children. No growth data of XLH children that started burosumab at a very young age, i.e., between 1 and 4 years, are available.Methods: We included 17 XLH children (11 boys) who started bur...

hrp0097p1-538 | Multisystem Endocrine Disorders | ESPE2023

Endocrine Late Effects In Survival Children With High-Risk Neuroblastoma From Italian Tertiary Hospital

Mirra Giulia , Deodati Annalisa , Ubertini Graziamaria , Elisa Amodeo Maria , Antonietta De Ioris Maria , Mastronuzzi Angela , Cavallo Federica , Grossi Armando

Background: The treatment of high-risk neuroblastoma still represents a clinical challenge in pediatric oncology. About 50% of children survive after a multimodal treatment based on conventional and high dose chemotherapy, surgery, radiotherapy, differentiating treatment and immunotherapy.Aim: To evaluate endocrine long-term sequels in a pediatric cohort with high-risk neuroblastoma.Patient...